PACTR202309818279236已完成4 期
Doxorubicin versus Idarubicin in Acute Myeloid Leukemia
ational Cancer Institute0 个研究点目标入组 244 人开始时间: 2023年8月21日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 244
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •18 years or older
- •Confirmed AML diagnosis
排除标准
- •Patients with current active second malignancy
- •AML M3 (Promyelocytic leukemia)
- •Patients with heart problems (low ejection fraction)
研究者
相似试验
已完成
2 期
Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid LeukemiaDi Novo Acute Myeloid LeukemiaNCT01700413Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias48
Unknown
2 期
IA14 Induction in Young Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04069208Peking Union Medical College Hospital42
已完成
3 期
DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AMLElderlyAMLNCT00589082Gruppo Italiano Malattie EMatologiche dell'Adulto
进行中（未招募）
1 期
Midostaurin in acute myeloid leukemia after allogeneic stem cell transplantatioMedDRA version: 21.1Level: LLTClassification code 10066764Term: Acute myeloid leukaemia progressionSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2019-000136-26-DEFriedrich-Schiller-Universität Jena86
已完成
3 期
Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2Acute Myeloid LeukemiaNCT00931138Acute Leukemia French Association420